138 related articles for article (PubMed ID: 19320777)
1. Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix.
Willems SM; Mohseny AB; Balog C; Sewrajsing R; Briaire-de Bruijn IH; Knijnenburg J; Cleton-Jansen AM; Sciot R; Fletcher CD; Deelder AM; Szuhai K; Hensbergen PJ; Hogendoorn PC
J Cell Mol Med; 2009 Jul; 13(7):1291-301. PubMed ID: 19320777
[TBL] [Abstract][Full Text] [Related]
2. GNAS1 mutations occur more commonly than previously thought in intramuscular myxoma.
Delaney D; Diss TC; Presneau N; Hing S; Berisha F; Idowu BD; O'Donnell P; Skinner JA; Tirabosco R; Flanagan AM
Mod Pathol; 2009 May; 22(5):718-24. PubMed ID: 19287459
[TBL] [Abstract][Full Text] [Related]
3. Detection of GNAS mutations in intramuscular / cellular myxomas as diagnostic tool in the classification of myxoid soft tissue tumors.
Sunitsch S; Gilg MM; Kashofer K; Gollowitsch F; Leithner A; Liegl-Atzwanger B
Diagn Pathol; 2018 Aug; 13(1):52. PubMed ID: 30111377
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel GNAS mutations in intramuscular myxoma using next-generation sequencing with single-molecule tagged molecular inversion probes.
Bekers EM; Eijkelenboom A; Rombout P; van Zwam P; Mol S; Ruijter E; Scheijen B; Flucke U
Diagn Pathol; 2019 Feb; 14(1):15. PubMed ID: 30736805
[TBL] [Abstract][Full Text] [Related]
5. A mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix.
Hara K; Saito T; Hayashi T; Yimit A; Takahashi M; Mitani K; Takahashi M; Yao T
Pathol Res Pract; 2015 Sep; 211(9):657-64. PubMed ID: 26160192
[TBL] [Abstract][Full Text] [Related]
6. Analysis of GNAS1 mutations in myxoid soft tissue and bone tumors.
Walther I; Walther BM; Chen Y; Petersen I
Pathol Res Pract; 2014 Jan; 210(1):1-4. PubMed ID: 24268734
[TBL] [Abstract][Full Text] [Related]
7. Odontogenic myxomas are not associated with GNAS1 mutations.
Friedrich RE; Scheuer HA; Assaf AT; Grob T; Zustin J
Anticancer Res; 2012 May; 32(5):2169-72. PubMed ID: 22593505
[TBL] [Abstract][Full Text] [Related]
8. Cell cycle and apoptosis regulatory proteins, proliferative markers, cell signaling molecules, CD209, and decorin immunoreactivity in low-grade myxofibrosarcoma and myxoma.
Cates JM; Memoli VA; Gonzalez RS
Virchows Arch; 2015 Aug; 467(2):211-6. PubMed ID: 25940995
[TBL] [Abstract][Full Text] [Related]
9. Juxta-articular myxoma and intramuscular myxoma are two distinct entities. Activating Gs alpha mutation at Arg 201 codon does not occur in juxta-articular myxoma.
Okamoto S; Hisaoka M; Meis-Kindblom JM; Kindblom LG; Hashimoto H
Virchows Arch; 2002 Jan; 440(1):12-5. PubMed ID: 11942570
[TBL] [Abstract][Full Text] [Related]
10. Myxoid tumours of soft tissue: the so-called myxoid extracellular matrix is heterogeneous in composition.
Willems SM; Schrage YM; Baelde JJ; Briaire-de Bruijn I; Mohseny A; Sciot R; Bovée JV; Hogendoorn PC
Histopathology; 2008 Mar; 52(4):465-74. PubMed ID: 18315599
[TBL] [Abstract][Full Text] [Related]
11. Molecular and clinicopathological features of appendiceal mucinous neoplasms.
Yanai Y; Saito T; Hayashi T; Akazawa Y; Yatagai N; Tsuyama S; Tomita S; Hirai S; Ogura K; Matsumoto T; Wada R; Yao T
Virchows Arch; 2021 Mar; 478(3):413-426. PubMed ID: 32821969
[TBL] [Abstract][Full Text] [Related]
12. Molecular biomarkers for progression of intraductal papillary mucinous neoplasm of the pancreas.
Kuboki Y; Shimizu K; Hatori T; Yamamoto M; Shibata N; Shiratori K; Furukawa T
Pancreas; 2015 Mar; 44(2):227-35. PubMed ID: 25423558
[TBL] [Abstract][Full Text] [Related]
13. [Intramuscular myxoma of the lower leg].
Luebke AM; Gocke C; Priemel M; Grob TJ; Zustin J
Pathologe; 2013 Jul; 34(4):360-3. PubMed ID: 23179208
[TBL] [Abstract][Full Text] [Related]
14. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
15. Karyotyping and analysis of GNAS locus in intramuscular myxomas.
Panagopoulos I; Gorunova L; Lobmaier I; Bjerkehagen B; Heim S
Oncotarget; 2017 Mar; 8(13):22086-22094. PubMed ID: 28160572
[TBL] [Abstract][Full Text] [Related]
16. Imaging mass spectrometry of myxoid sarcomas identifies proteins and lipids specific to tumour type and grade, and reveals biochemical intratumour heterogeneity.
Willems SM; van Remoortere A; van Zeijl R; Deelder AM; McDonnell LA; Hogendoorn PC
J Pathol; 2010 Dec; 222(4):400-9. PubMed ID: 20839361
[TBL] [Abstract][Full Text] [Related]
17. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
[TBL] [Abstract][Full Text] [Related]
18. Next generation sequencing for GNAS uncovers CD34 as a sensitive marker for intramuscular myxoma.
Libbrecht L; Bempt IV; Schubert T; Sciot R; Galant C
Ann Diagn Pathol; 2019 Dec; 43():151409. PubMed ID: 31726379
[TBL] [Abstract][Full Text] [Related]
19. Activating Gs(alpha) mutation in intramuscular myxomas with and without fibrous dysplasia of bone.
Okamoto S; Hisaoka M; Ushijima M; Nakahara S; Toyoshima S; Hashimoto H
Virchows Arch; 2000 Aug; 437(2):133-7. PubMed ID: 10993273
[TBL] [Abstract][Full Text] [Related]
20. Mutation profile of high-grade appendiceal mucinous neoplasm.
Liao X; Vavinskaya V; Sun K; Hao Y; Li X; Valasek M; Xu R; Polydorides AD; Houldsworth J; Harpaz N
Histopathology; 2020 Feb; 76(3):461-469. PubMed ID: 31491041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
